Berglund G, Andersson O, Larsson O, Wilhelmsen L
Acta Med Scand. 1976;199(6):499-506. doi: 10.1111/j.0954-6820.1976.tb06770.x.
The antihypertensive effect and side-effects during 12 months' treatment with bendroflumethiazide and propranolol have been compared in two randomly selected, equally large groups (n= 53) of previously untreated male hypertensives. Systolic BP above 170 or diastolic BP above 105 mmHg on two occasions were defined as hypertension. The same BP reduction was achieved in both groups. During the 12 months' treatment one subject on bendroflumethiazide developed diabetes mellitus and one on propranolol developed cardiac decompensation. None developed gout. Contrary to what had been presumed, glucose tolerance improved during 12 months' treatment with both agents, while there were no changes in fasting blood sugar, insulin or triglyceride concentrations. No changes were found in serum potassium or total body potassium during 12 months' bendroflumethiazide treatment, while serum potassium increased during treatment with propranolol. Uric acid increased slightly during treatment with both agents. Prolongation of the follow-up to 24 months did not change any of the findings regarding metabolic changes during treatment. The frequency of subjective side-effects decreased to the same extent during treatment with both drugs. It is concluded that bendroflumethiazide and propranolol are equally useful as antihypertensive agents and that the risk of impariment of glucose metabolism and potassium balance seems to be very slight during treatment with bendroflumethiazide in mild hypertension.
在两组随机选取的、数量相等（n = 53）的未经治疗的男性高血压患者中，比较了苄氟噻嗪和普萘洛尔治疗12个月期间的降压效果及副作用。两次收缩压高于170 mmHg或舒张压高于105 mmHg被定义为高血压。两组的血压降低幅度相同。在12个月的治疗期间，一名服用苄氟噻嗪的受试者患了糖尿病，一名服用普萘洛尔的受试者出现了心脏代偿失调。无人患痛风。与预期相反，在两种药物治疗的12个月期间，葡萄糖耐量均有所改善，而空腹血糖、胰岛素或甘油三酯浓度均无变化。在苄氟噻嗪治疗的12个月期间，血清钾和总体钾均无变化，而在普萘洛尔治疗期间血清钾升高。两种药物治疗期间尿酸均略有升高。将随访延长至24个月并未改变治疗期间代谢变化的任何结果。两种药物治疗期间主观副作用的发生率均以相同程度下降。结论是，苄氟噻嗪和普萘洛尔作为降压药同样有效，在轻度高血压患者中使用苄氟噻嗪治疗期间，葡萄糖代谢和钾平衡受损的风险似乎非常小。
